Catherine Welsh

Associate Professor of Clinical

  • 721 Citations
19922017
If you made any changes in Pure, your changes will be visible here soon.

Fingerprint Dive into the research topics where Catherine Welsh is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 1 Similar Profiles
ADP-Ribosylation Factors Medicine & Life Sciences
docetaxel Medicine & Life Sciences
Guanine Nucleotides Medicine & Life Sciences
Guanosine Triphosphate Medicine & Life Sciences
Cyclin D1 Medicine & Life Sciences
Breast Neoplasms Medicine & Life Sciences
Cholera Toxin Medicine & Life Sciences
rho GTP-Binding Proteins Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Projects 2001 2006

rho GTP-Binding Proteins
Cell Cycle
Breast Neoplasms
Cyclin D1
Epithelial Cells

Research Output 1992 2017

  • 721 Citations
  • 18 Article
  • 1 Review article
2 Citations (Scopus)

A Breast Cancer Review: Through the Eyes of the Doctor, Nurse, and Patient

Klevos, G., Ezuddin, N. S., Vinyard, A., Ghaddar, T., Gort, T., Almuna, A., Abisch, A. & Welsh, C., Sep 1 2017, In : Journal of Radiology Nursing. 36, 3, p. 158-165 8 p.

Research output: Contribution to journalReview article

Nurses
Breast Neoplasms
Breast
Psychology
Physicians
49 Citations (Scopus)

Phase 2 study of neoadjuvant treatment with NOV-002 in combination with doxorubicin and cyclophosphamide followed by docetaxel in patients with HER-2 negative clinical stage II-IIIc breast cancer

Montero, A. J., Diaz-Montero, C. M., Deutsch, Y. E., Hurley, J., Koniaris, L. G., Rumboldt, T., Yasir, S., Jorda, M., Garret-Mayer, E., Avisar, E., Slingerland, J. M., Silva, O., Welsh, C., Schuhwerk, K., Seo, P. H., Pegram, M. D. & Glück, S., Feb 1 2012, In : Breast Cancer Research and Treatment. 132, 1, p. 215-223 9 p.

Research output: Contribution to journalArticle

docetaxel
Neoadjuvant Therapy
Doxorubicin
Cyclophosphamide
Breast Neoplasms
53 Citations (Scopus)

Final results of a phase II study of nab-paclitaxel, bevacizumab, and gemcitabine as first-line therapy for patients with HER2-negative metastatic breast cancer

Lobo, C., Lopes, G., Baez, O., Castrellon, A., Ferrell, A., Higgins, C., Hurley, E., Hurley, J., Reis, I., Richman, S. P., Seo, P. H., Silva, O., Slingerland, J. M., Tukia, K., Welsh, C. & Glück, S., Sep 1 2010, In : Breast Cancer Research and Treatment. 123, 2, p. 427-435 9 p.

Research output: Contribution to journalArticle

gemcitabine
Breast Neoplasms
Disease-Free Survival
Nanoparticles
Therapeutics

Erratum: Timing of cyclin D1 expression within G1 phase is controlled by Rho (Nature Cell Biology (2001) 3 (950-957))

Welsh, C., Roovers, K., Villanueva, J., Liu, Y., Schwartz, M. A. & Assoian, R. K., Dec 1 2009, In : Nature Cell Biology. 11, 12

Research output: Contribution to journalArticle

Cyclin D1
G1 Phase
Cell Biology
11 Citations (Scopus)

A phase II trial of split, low-dose docetaxel and low-dose capecitabine: A tolerable and efficacious regimen in the first-line treatment of patients with HER2/neu-negative metastatic breast cancer

Silva, O., Lopes, G., Morgenzstern, D., Lobo, C., Doliny, P., Santos, E., Abdullah, S., Gautam, U., Reis, I., Welsh, C., Slingerland, J. M., Hurley, J. & Gluck, S., Jan 1 2008, In : Clinical Breast Cancer. 8, 2, p. 162-167 6 p.

Research output: Contribution to journalArticle

docetaxel
Breast Neoplasms
Therapeutics
Appointments and Schedules
Capecitabine